Acellular soft tissue-derived matrices and methods for preparing same
Compositions including a first soft tissue-derived matrix and a second soft tissue-derived matrix are provided, as well as methods of making such compositions. In some embodiments, the composition comprises dilapidated, decellularized adipose tissue-derived matrix and dilapidated, decellularized fascial tissue-derived matrix, which may be combined in various proportions. Such adipose-fascia matrix compositions provide improved volume retention when implanted into a patient. The composition may further include exogenous cells or other substances, and/or a carrier. The composition is suitable for use in plastic surgery procedures, including reconstructive or cosmetic surgery procedures, as well as procedures for wound treatment and tissue regeneration. The methods for making the compositions may involve separation of first and second soft tissues from one another, followed by performing one or more treatments on the separated soft tissues, then combining the treated soft tissues and, optionally, performing one or more additional treatments on the combined soft tissues.
1. A method of preparing a composition comprising an adipose component derived from adipose tissue and a fascia component derived from fascia tissue, said method comprising the steps of:
a) delipidizing the adipose tissue;
b) decellularizing the adipose tissue;
c) optionally disinfecting the adipose tissue;
d) optionally delipidizing the fascia tissue;
e) decellularizing the fascia tissue;
f) optionally disinfecting the fascia tissue; and
g) combining the adipose tissue and the fascia tissue to form the composition,
before, after, or during any one or more of the delipidizing, decellularizing, and disinfecting steps and
in a predetermined ratio of adipose tissue to fascia tissue in a range of from about 99:1 to about 1:99 by weight based on the total weight of the adipose and fascia components,
whereby the composition provides improved volume retention at an implantation site after passage of a minimum period of time from implantation of the composition in a subject, wherein improved volume retention is improved compared to a composition having a predetermined ratio of 100:0.
2. The method of claim 1 , wherein any one or more of the delipidizing, decellularizing and disinfecting steps are performed concurrently with, or in any order relative to, each another.
3. The method of claim 1 , further comprising one or more steps of disinfecting, at least partially drying, size reduction, and packaging, any one or more of which is performed on one or both of the adipose and fascia tissues either before or after the combining step.
4. The method of claim 1 , wherein the adipose and fascia tissues are attached to each other before performing any delipidizing or decellularizing steps, wherein any one or more of the delipidizing, decellularizing and disinfecting steps are performed on the attached adipose and fascia tissues.
5. The method of claim 1 , wherein the adipose and fascia tissues are attached to each other before performing any delipidizing or decellularizing steps, wherein the method further comprises the step of separating the adipose tissue from the fascia tissue before or after performing any one or more of the delipidizing, decellularizing and disinfecting steps are performed on the attached adipose and fascia tissues, such that at least one of the delipidizing, decellularizing and disinfecting steps is performed on the separated adipose tissue and the fascia tissue.
6. The method of claim 5 , further comprising combining the adipose and fascia tissues together to form recombined adipose and fascia tissues, during or after performance of at least one of the delipidizing, decellularizing and disinfecting steps on at least one of the separated adipose tissue and fascia tissue.
7. The method of claim 1 , wherein the predetermined ratio is at least 4:1.
8. The method of claim 1 , wherein the predetermined ratio is at least about 1:1.
9. The method of claim 1 , wherein the minimum period of time from implantation is at least 3 weeks.
10. The method of claim 1 , wherein the minimum period of time from implantation is at least 12 weeks.
11. The method of claim 1 , further comprising one or more steps of disinfecting, at least partially drying, size reduction, and packaging, any one or more of which is performed on one or both of the adipose and fascia tissues either before or after the combining step.
12. The method of claim 6 , comprising the sequential steps of:
performing size reduction on the attached adipose and fascia tissues;
separating the adipose tissue from the fascia tissue;
independently delipidizing one or both of the adipose tissue and the fascia tissue, either sequentially or at least partially concurrently;
independently decellularizing one or both of the adipose tissue and the fascia tissue, either sequentially or at least partially concurrently;
independently disinfecting one or both of the adipose tissue and the fascia tissue, either sequentially or at least partially concurrently;
independently at least partially drying the adipose tissue and the fascia tissue, either sequentially or at least partially concurrently; and
independently performing size reduction on each of the adipose tissue and the fascia tissue, either sequentially or at least partially concurrently, to produce adipose tissue having particulate form and fascia tissue having particulate form; and
combining the particulate adipose tissue and the particulate fascia tissue to form recombined adipose and fascia tissues.
13. The method of claim 6 , comprising the sequential steps of:
performing size reduction on the attached adipose and fascia tissues;
separating the adipose tissue from the fascia tissue;
independently delipidizing at least one of the adipose tissue and the fascia tissue, either sequentially or at least partially concurrently;
independently decellularizing at least one of the adipose tissue and the fascia tissue, either sequentially or at least partially concurrently;
combining the adipose tissue and the fascia tissue to form recombined adipose and fascia tissues;
disinfecting the recombined adipose and fascia tissues;
optionally, at least partially drying the recombined adipose and fascia tissues; and
optionally, performing size reduction on the recombined adipose and fascia tissues.
14. The method of claim 13 , wherein drying is performed and the composition produced is substantially dried and has a water content of less than about 20%, by weight, based on the total weight of the adipose and fascia components.
15. The method of claim 13 , wherein partially drying is performed and the composition produced has a water content of at least about 20%, by weight, based on the total weight of the adipose and fascia components.
16. The method of claim 13 , wherein no drying is performed and the composition produced has a water content of at least about 20%, by weight, based on the total weight of the adipose and fascia components, and wherein the composition is ready to use without requiring rehydration.
17. The method of claim 1 , wherein the step of delipidating the adipose tissue is performed with a polar organic solvent, the step of delipidating the fascia tissue is performed with a polar organic solvent, or both.
18. The method of claim 1 , wherein the step of decellularizing the adipose tissue is performed with a detergent solution, the step of decellularizing the fascia tissue is performed with a detergent solution, or both.
19. The method of claim 1 , wherein the step of decellularizing the adipose tissue is performed with a hypertonic solution, the step of decellularizing the fascia tissue is performed with a hypertonic solution, or both.